Versant Ventures

Firefly

Biotech

J&J makes $1B bet on emerging DAC space by netting Firefly Bio

Johnson & Johnson has paid $1 billion upfront to buy itself a degrader antibody conjugate platform via the acquisition of Firefly Bio.

James Waldron Jun 8, 2026 10:05am

Sunrise over foggy forest in Tuscany Italy

Versant's Dayra dawns with $50M Biogen pact

Nov 24, 2025 10:28am

Dark and dramatic sky with sunlight

After 'complete standstill,' biotech market reaches new normal

Aug 20, 2025 11:04am

Parachute over a mountain in Switzerland

Galapagos CEO eyes exit as spinout names leader—Chutes & Ladders

Apr 25, 2025 8:30am

abstract black agate background with golden veins fake painted artificial stone marble texture

Versant unveils new autoimmune biotech with $100M fundraise

Apr 24, 2025 8:00am

weight loss scale weigh measure tape obesity overweight

Versant launches another obesity biotech with $65M series A

Jan 28, 2025 8:35am